Format

Send to

Choose Destination
Dermatol Ther (Heidelb). 2017 Sep;7(3):281-292. doi: 10.1007/s13555-017-0187-0. Epub 2017 Jun 21.

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.

Author information

1
Department of Dermatology, University of California San Francisco, San Francisco, CA, USA. Mio.Nakamura@ucsf.edu.
2
University of California Los Angeles, Los Angeles, CA, USA.
3
Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.

Abstract

INTRODUCTION:

Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway.

METHODS:

We summarize the available phase III results to date, establishing the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis.

RESULTS:

Currently, there are available data of up to 48 weeks from two Phase III, multicenter, randomized, double-blind, placebo- and comparator-controlled clinical trials, VOYAGE 1 and VOYAGE 2. At week 16, the proportion of patients attaining at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) was 73.3% in VOYAGE 1 and 70.0% in VOYAGE 2. Guselkumab remained efficacious through 48 weeks of treatment. Guselkumab maintained a satisfactory safety profile with the most frequently reported adverse events being nasopharyngitis, headache, and upper respiratory tract infection.

CONCLUSION:

Phase III trials of Guselkumab suggest a favorable efficacy and safety profile of this novel drug. Although further studies are needed to assess long-term safety and efficacy, based on the results to date, guselkumab appears to be a promising therapeutic option for moderate-to-severe plaque-type psoriasis.

KEYWORDS:

Anti-interleukin-23; Biologics; Guselkumab; Phase III; Psoriasis; VOYAGE

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center